Navigation Links
Renhuang Signs Exclusive Purchase Agreement for Siberian Ginseng
Date:7/9/2010

HARBIN, China, July 9 /PRNewswire-Asia-FirstCall/ -- Renhuang Pharmaceuticals, Inc. (NYSE Amex: CBP) ("Renhuang" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ("TCM"), today announced that on July 8, 2010, the Company signed an Acquisition Agreement (the "Agreement") with Yichun Red Star Forest Bureau of Heilongjiang Province ("the Forest Bureau") for indefinite exclusive access to 100,000 acres of wild Siberian Ginseng in Heilongjiang Province. Siberian Ginseng is a plant with medically-established anti-depressant and mood regulation qualities and is also an active ingredient in the Company's market-leading line of all-natural anti-depressant medications.

Under the terms of the Agreement, Renhuang will be granted permanent exclusive rights to purchase the wild Siberian Ginseng grown on 100,000 acres. The Siberian Ginseng plant yield is expected to amount to an estimated 500 tons annually. The Siberian Ginseng fields will be maintained and harvested by personnel supervised by the Forest Bureau and the Company will pay a lower than prevailing fair market price for the Siberian Ginseng harvested. Renhuang will be responsible for continued maintenance and protection of wild resources to make this area a professional Siberian Ginseng base that produces additional Ginseng. In addition to generating income for the Forest Bureau, this resource base will provide employment opportunities for local farmers.

"We are excited about securing exclusive access to the world's finest quality wild Siberian Ginseng," said Mr. Shaoming Li, Chairman and CEO of Renhuang. "It is also a great honor to work on a project with Yichun Red Star Forest Bureau to assist in the economic development of the region and improve the cultivation of this precious natural resource. This Agreement provides us a reliable and abundant supply of Siberian Ginseng at an attractive price, resulting in a significant competitive advantage in the market."

ABOUT RENHUANG PHARMACEUTICALS, INC.

Renhuang Pharmaceuticals, Inc. is engaged in the research, development, manufacturing, and distribution of botanical products, bio-pharmaceutical products, and traditional Chinese medicines ("TCM"), in the People's Republic of China. All of the Company's products are produced at its three GMP-certified production facilities in Ah City, Dongfanghong and Qingyang. The Company distributes its botanical anti-depression and nerve-regulation products, biopharmaceutical products, and botanical antibiotic and OTC TCMs through its network of over 3,000 distributors and over 70 sales centers across 24 provinces in China. Company Website: http://www.renhuang.com .

Safe Harbor Statement

This press release contains certain statements that may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based upon management's beliefs, assumptions and expectations of the Company's future operations and economic performance, taking into account the information currently available to management. These statements are not statements of historical fact. Forward-looking statements involve risks and uncertainties, some of which are not currently known that may cause actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial condition expressed or implied in any forward-looking statements. These forward-looking statements are based on current plans and expectations and are subject to a number of uncertainties including, but not limited to, the Company's competitive advantages as a result of the acquisition agreement with Yichun Red Star Forest Bureau of Heilongjiang Province, ability to manage expansion of its operations effectively, and other factors detailed in the Company's annual report on Form 10-K and other filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented herein.

    For more information, please contact:

    Company Contact:
     Renhuang Pharmaceuticals, Inc.
     Ms. Portia Tan, IR Contact
     Tel:   +86-451-8260-2162
     Email: ir@renhuang.com

    CCG Investor Relations:
     Mr. Mark Collinson, Partner
     Tel:   +1-310-954-1343 (Los Angeles)
     Email: mark.collinson@ccgir.com
     Web:   http://www.ccgirasia.com

     Mr. Crocker Coulson, President
     Tel:   +1-646-213-1915 (New York)
     Email: crocker.coulson@ccgir.com


'/>"/>
SOURCE Renhuang Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Renhuang Announces Fiscal Year 2010 Guidance
2. Renhuang Announces Price Increase on Shengmai Granules
3. Renhuang Schedules Conference Call to Discuss FY 2010 First Quarter Results
4. Renhuang Pharmaceuticals Announces Continual Improvement in Days Sales Outstanding
5. Renhuang Appoints New Director and Establishes Nominating and Compensation Committee
6. Renhuang Pharmaceuticals Announces Plans to Introduce Qing Re Jie Du Oral Liquid
7. Renhuang Elected as Deputy Chair Unit of Heilongjiang Medical Association
8. Renhuang Pharmaceuticals Exhibits All-Natural Products at the 107th China Import and Export Fair
9. Renhuang Announces Successful Preliminary Review of Its Patent Application for Schisandra Total Lignin Extraction Method
10. Renhuang Appoints PricewaterhouseCoopers to Develop a SOX 404 Compliance Program
11. Renhuang Schedules Conference Call to Discuss FY 2010 Second Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... The pen needles market is projected to ... billion in 2016, growing at a CAGR of 11.2% ... Over the years, the pen needles market has witnessed ... growing demand for safety injections in the healthcare industry. ... pen needles with an aim to reduce pain, increase ...
(Date:12/6/2016)... , Dec. 6, 2016  Nearly 30 million people ... from the epidemic of diabetes. 1 However, nearly ... elevated glucose levels (hyperglycemia) and significant glucose variability. 2 ... complications, including cardiovascular events. If left untreated, hyperglycemia can ... eye disease or blindness. 3 As ...
(Date:12/6/2016)... Fla. , Dec. 6, 2016 With opioids commonly ... newcomer in the prescription drug market that has led to nationwide ... approximately seven to eight times stronger than heroin or morphine, resulting ... ... Suzanne Smolkin , vice president, clinical operations, Behavioral Health for HMC ...
Breaking Medicine Technology:
(Date:12/7/2016)... , ... December 07, 2016 , ... One of two ... of the securement tape is painful for her. "This is why the co-inventor and ... heads," she said. , They then created a prototype of the patent-pending AV-AIR, a ...
(Date:12/7/2016)... ... ... Sharon Kleyne, host of the nationally syndicated radio program, The Sharon Kleyne ... declared on her radio program in November 2016 the need to educate people about ... leaders in corporate America, they are trying to take advantage of successful algorithms and ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... is condemning "scam operations" carried out by unethical locksmith companies and is urging ... to a halt. According to Texas Premier Locksmith, these fraudulent locksmith services take ...
(Date:12/7/2016)... ... December 07, 2016 , ... Gensuite ... Brilliance Awards under the Best New Product Launch category. Gensuite’s entry on their ... experience. , BOC Global Events & Training Group is a professional event and ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... “Tomorrow Trump ... Donald Trump bringing greatness back to the presidency and to America. “Tomorrow Trump Goes ... to do as much as she can for this country. , Nancy attributes her ...
Breaking Medicine News(10 mins):